termsTerm
FGFR2 fusions and rearrangements
A broken-and-rejoined FGFR2 gene that drives about one in eight intrahepatic bile duct cancers and can be switched off with pills.
Detected by RNA or DNA sequencing; partners are diverse (BICC1 most common). Pemigatinib (ORR 37%) and futibatinib (ORR 42%) are approved; acquired resistance arises through FGFR2 kinase-domain mutations (N550, V565 gatekeeper) that next-generation inhibitors (tinengotinib, RLY-4008 lirafugratinib) target. Hyperphosphataemia is the class effect.
Genomics: what this kind of term is about · animated schematic, not to scale
Category
Genomics